Inogen Inc (INGN) Shares Sold by Royal Bank of Canada

Royal Bank of Canada cut its position in shares of Inogen Inc (NASDAQ:INGN) by 13.7% during the 1st quarter, HoldingsChannel.com reports. The firm owned 242,072 shares of the medical technology company’s stock after selling 38,374 shares during the period. Royal Bank of Canada’s holdings in Inogen were worth $29,736,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Sei Investments Co. grew its holdings in shares of Inogen by 10.5% in the 1st quarter. Sei Investments Co. now owns 3,073 shares of the medical technology company’s stock worth $377,000 after acquiring an additional 293 shares during the last quarter. Mason Street Advisors LLC grew its holdings in shares of Inogen by 7.8% in the 1st quarter. Mason Street Advisors LLC now owns 4,799 shares of the medical technology company’s stock worth $590,000 after acquiring an additional 348 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in shares of Inogen by 0.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 48,987 shares of the medical technology company’s stock worth $6,014,000 after acquiring an additional 351 shares during the last quarter. Comerica Bank grew its holdings in shares of Inogen by 1.6% in the 1st quarter. Comerica Bank now owns 25,164 shares of the medical technology company’s stock worth $3,554,000 after acquiring an additional 392 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Inogen by 8.0% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,910 shares of the medical technology company’s stock worth $849,000 after acquiring an additional 510 shares during the last quarter. Institutional investors own 97.86% of the company’s stock.

INGN has been the topic of a number of recent research reports. KeyCorp initiated coverage on Inogen in a report on Wednesday, June 6th. They issued an “equal weight” rating on the stock. JPMorgan Chase & Co. lifted their target price on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, May 1st. BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a report on Friday, March 2nd. Needham & Company LLC lifted their target price on Inogen from $150.00 to $215.00 and gave the stock a “strong-buy” rating in a report on Tuesday, May 1st. Finally, Piper Jaffray Companies lifted their target price on Inogen to $190.00 and gave the stock an “overweight” rating in a report on Monday, April 30th. Two analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and a consensus target price of $178.00.

Shares of Inogen opened at $185.94 on Friday, MarketBeat reports. The firm has a market capitalization of $3.86 billion, a PE ratio of 121.38, a price-to-earnings-growth ratio of 4.58 and a beta of 1.10. Inogen Inc has a 12 month low of $89.01 and a 12 month high of $194.23.

Inogen (NASDAQ:INGN) last issued its earnings results on Monday, April 30th. The medical technology company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.19. The business had revenue of $79.05 million during the quarter, compared to analysts’ expectations of $63.86 million. Inogen had a return on equity of 14.81% and a net margin of 9.36%. Inogen’s revenue was up 50.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.27 earnings per share. research analysts expect that Inogen Inc will post 1.77 EPS for the current year.

In other news, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction on Tuesday, April 17th. The stock was sold at an average price of $139.82, for a total value of $139,820.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at $139,820. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $139.79, for a total value of $349,475.00. Following the completion of the sale, the executive vice president now directly owns 8,374 shares of the company’s stock, valued at approximately $1,170,601.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,589 shares of company stock valued at $10,581,530. 5.29% of the stock is currently owned by insiders.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply